A synthetic cell-penetrating peptide antagonizing TrkA function suppresses neuropathic pain in mice

Journal of Pharmacological Sciences

Volumn 114, Issue 1, 2010, Pages 79-84

  Ma, Wei Ying ^a,c   Murata, Eri ^a   Ueda, Koyo ^a   Kuroda, Yoshihiro ^b   Cao, Ming Hui ^c   Abe, Mineo ^d   Shigemi, Kenji ^a   Hirose, Munetaka ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b HIMEJI DOKKYO UNIVERSITY   (Japan)

^c SUN YAT SEN UNIVERSITY   (China)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Cell penetrating peptide; Neuropathic pain; Tat; TrkA

Indexed keywords

CELL PENETRATING PEPTIDE; IPTRK 3; PROTEIN FOS; PROTEIN TYROSINE KINASE A; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HYPERALGESIA; LUMBAR SPINAL CORD; MALE; MOUSE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCIATIC NERVE; TACTILE STIMULATION;

EID: 77957941177     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10119FP     Document Type: Article

References (24)

1. Haanpää ML, Backonja M-M, Bennett MI, Bouhassira D, Cruccu G, Hansson PT, et al. Assessment of neuropathic pain in primary care. Am J Med. 2009;122:S13-S21.
2. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635.
3. O'Conner AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122:S22-S32.
4. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356-363.
5. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci. 2002;5 Suppl:1062-1067.
6. Thacker MA, Clark AK, Marchand F, McMahon SB. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg. 2007;105:838-847.
7. Dray A. Neuropathic pain: emerging treatments. Br J Anaesth. 2008;101:48-58.
8. Hirose M, Takatori M, Kuroda Y, Abe M, Murata E, Isada T, et al. Effect of synthetic cell-penetrating peptides on TrkA activity in PC12 cells. J Pharmacol Sci. 2008;106:107-113.
9. Ueda K, Hirose M, Murata E, Takatori M, Ueda M, Ikeda H, et al. Local administration of a synthetic cell-penetrating peptide antagonizing TrkA function suppresses inflammatory pain in rats. J Pharmacol Sci. 2010;112:438-443.
10. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain. 1990;43:205-218.
11. Catheline G, Le Guen S, Honoré P, Besson JM. Are there longterm changes in the basal or evoked Fos expression in the dorsal horn of the spinal cord of the mononeuropathic rat? Pain. 1999;80:347-357.
12. Zimmermann M. The guidelines on ethical standards for investigation of experimental pain in animals. Pain. 1983;16:109-110.
13. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32:77-88.
14. Ma QP, Woolf CJ. Basal and touch evoked fos-like immunoreactivity during experimental inflammation in the rat. Pain. 1996;67:307-316.
15. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52:77-92.
16. Herzberg U, Eliav E, Dorsey JM, Gracely RH, Kopin IJ. NGF involvement in pain induced by chronic constriction injury of the rat sciatic nerve. Neuroreport. 1997;8:1613-1618.
17. Oh EJ, Yoon YW, Lee SE, Hong SK. Changes in nerve growth factor levels in dorsal root ganglia and spinal nerves in a rat neuropathic pain model. Exp Brain Res. 2000;130:93-99.
18. Wild KD, Bian D, Zhu D, Davis J, Bannon AW, Zhang TJ, et al. Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance. J Pharmacol Exp Ther. 2007;322:282-287.
19. Ugolini G, Marinelli S, Covaceuszach S, Cattaneo A, Pavone F. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc Natl Acad Sci U S A. 2007;104:2985-2990.
20. Michael GL, Kaya E, Averill S, Rattray M, Clary DO, Priestley JV. TrkA immunoreactive neurons in the rat spinal cord. J Comp Neurol. 1997;385:441-455.
21. Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci. 2003;23:2899-2910.
22. Schorderet DF, Manzi V, Canola K, Bonny C, Arsenijevic Y, Munier FL, et al. D-TAT transporter as an ocular peptide delivery system. Clin Experiment Ophthalmol. 2005;33:628-635.
23. Harris JA. Using c-fos as a neural marker of pain. Brain Res Bull. 1998;45:1-8.
24. Munglani R, Hunt SP. Molecular biology of pain. Br J Anaesth. 1995;75:186-192.